The reviewed pricing under offtake is HUGE!
The Company has continued to undertake price reviews with its offtake partners (as allowed
for under its off-take agreements) to ensure pricing outcomes remain aligned with the
prevailing market price for spodumene concentrate under longer dated offtake terms.
While final pricing mechanisms are not yet completely agreed with all offtake customers,
spodumene pricing is expected to be revised upwards (relative to the historical norm) and
would currently support pricing in the range of approximately USD$1650-$1800/dmt CIF
China (SC6.0 basis), subject to any further provisional pricing adjustment.
Ann: September 2021 Quarterly Activities Report, page-4
-
- There are more pages in this discussion • 56 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PLS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.89 |
Change
0.000(0.00%) |
Mkt cap ! $8.699B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | $3.03 | $2.84 | $58.14K | 17.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 7240 | $3.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.45 | 7900 | 2 |
View Market Depth
| Last trade - 09.56am 25/07/2024 (20 minute delay) ? |
| PLS (ASX) Chart |
Day chart unavailable